021-51111890
购物车（）
sales@molnova.cn
Vatalanib
CAS No. 212141-51-0
Vatalanib ( PTK787;PTK/ZK;CGP-79787D;CGP-79787;ZK-222584 )
产品货号. M13374 CAS No. 212141-51-0
A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥243 | 有现货 |
|
| 10MG | ￥381 | 有现货 |
|
| 25MG | ￥510 | 有现货 |
|
| 50MG | ￥543 | 有现货 |
|
| 100MG | ￥786 | 有现货 |
|
| 200MG | ￥1280 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Vatalanib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
-
产品描述A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ; shows no activity against EGFR, FGFR-1, c-Met, and Tie-2, or c-Src, c-Abl, and PKC-α; blocks the VEGF-induced receptor autophosphorylation in CHO cells ectopically expressing the KDR receptor with IC50 of 34 nM; inhibits EGF and PDGF-induced angiogenesis in a growth factor implant model (25-100 mg/kg).Ovarian Cancer Phase 1 Discontinued
-
同义词PTK787;PTK/ZK;CGP-79787D;CGP-79787;ZK-222584
-
通路Angiogenesis
-
靶点VEGFR
-
受体PDGFRβ;VEGFR1/FLT1;VEGFR2/Flk1;VEGFR2/KDR;VEGFR3/FLT4
-
研究领域Cancer
-
适应症Ovarian Cancer
化学信息
-
CAS Number212141-51-0
-
分子量419.73
-
分子式C20H17Cl3N4
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4)C=C1.[H]Cl.[H]Cl
-
化学全称1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, hydrochloride (1:2)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Bold G, et al. J Med Chem. 2000 Jun 15;43(12):2310-23.
2. Wood JM, et al. Cancer Res. 2000 Apr 15;60(8):2178-89.
3. Drevs J, et al. Cancer Res. 2000 Sep 1;60(17):4819-24.
4. Hess C, et al. Br J Cancer. 2001 Dec 14;85(12):2010-6.
2. Wood JM, et al. Cancer Res. 2000 Apr 15;60(8):2178-89.
3. Drevs J, et al. Cancer Res. 2000 Sep 1;60(17):4819-24.
4. Hess C, et al. Br J Cancer. 2001 Dec 14;85(12):2010-6.
产品手册
关联产品
-
Fruquintinib
A potent and highly selective small molecule inhibitor of VEGFR1/2/3 with IC50 of 33/3/5/0.5 nM, respectively.
-
Pz-1
Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
-
TAS-115
TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).
